Menu Search
Equities

Cann Group Ltd

CVJ:BER

Cann Group Ltd

Actions
  • Price (EUR)0.0372
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-66.52%
  • Beta--
Data delayed at least 15 minutes, as of Feb 29 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cann Group Limited is an Australia-based company that is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research, cultivation and good manufacturing practices (GMP) manufacturing facilities are located in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.

  • Revenue in AUD (TTM)16.45m
  • Net income in AUD-29.28m
  • Incorporated2015
  • Employees40.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.